Covid: Centre stops allocation of Remdesivir to states as supply crunch resolves | Latest News India - Hindustan Times
close_game
close_game

Covid: Centre stops allocation of Remdesivir to states as supply crunch resolves

By, Hindustan Times, New Delhi
May 30, 2021 12:40 AM IST

To address shortages and prevent black-marketing of various drugs used in the treatment of Covid-19, the government had stepped in to allocate these to states as cases of the infection shot up in the second wave.

The Centre has decided to step out of the state-wise allocation of the antiviral drug Remdesivir used in Covid treatment after its production increased tenfold since April, the government said on Saturday.

Boxes of Remdesivir, an antiviral drug used to treat Covid-19 symptoms. (PTI)
Boxes of Remdesivir, an antiviral drug used to treat Covid-19 symptoms. (PTI)

To address shortages and prevent black-marketing of various drugs used in the treatment of Covid-19, the government had stepped in to allocate these to states as cases of the infection shot up in the second wave.

Hindustan Times - your fastest source for breaking news! Read now.

The production capacity has increased from a million doses a month to 10 million, according to Mansukh Mandaviya, minister of state for chemicals and fertilisers. The number of plants manufacturing the drug, the patent for which is held by Gilead Sciences, has increased from 20 to 60 in a month.

“Now the country has enough Remdesivir as the supply is much more than the demand,” the minister said in a release. The government has also decided to purchase five million vials and create a stock so that there is no shortage if cases surge again.

Also read| Don’t lower guard: Experts warn against Covid 3rd wave in K’taka

When Covid-19 infections shot up in India in April, there was an acute shortage of the antiviral drug that is used by doctors for treating patients with moderate disease. At the time, Gilead Sciences donated 450,000 doses of the medicine while India was scaling up domestic production.

To be sure, the World Health Organisation recommended against the use of the medicine seeing no mortality or any other benefit in November last year. India continues to use the drug, which is part of its clinical management protocol as well.

“Initially, it was said to reduce the period of hospitalisation. However, since then several global studies have shown no benefit and many countries have stopped using the drug. In India, we do not have a large randomised control trial but clinicians have seen benefit of the medicine in their patients. So, there is no big centre in the country that is not using the drug in moderate to severe cases,” said Dr Rajesh Chawla, senior pulmonologist at Indraprastha Apollo hospital.

The government still controls allocation of other Covid-19 drugs such as Tocilizumab, which is not manufactured in India.

Unveiling Elections 2024: The Big Picture', a fresh segment in HT's talk show 'The Interview with Kumkum Chadha', where leaders across the political spectrum discuss the upcoming general elections. Watch now!

Get Current Updates on India News, Election 2024, Arvind Kejriwal News Live, Bihar Board 10th Result 2024 Live along with Latest News and Top Headlines from India and around the world.
SHARE THIS ARTICLE ON
Share this article
  • ABOUT THE AUTHOR
    author-default-90x90

    Anonna Dutt is a health reporter at Hindustan Times. She reports on Delhi government’s health policies, hospitals in Delhi, and health-related feature stories.

SHARE
Story Saved
Live Score
OPEN APP
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Friday, March 29, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On